Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
Wednesday, July 29, 2026 1 min read
Key Takeaway: Johnson & Johnson has announced a collaboration with Sail Biomedicines to enhance in vivo CAR-T therapies aimed at treating immune-mediated diseases. This partnership will focus on advancing Sail's lead program and expanding its platform technology to target additional therapeutic areas. The collaboration signifies a commitment to innovation in autoimmune disease treatment.
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration aims to advance in vivo CAR-T therapies.
Potential to transform treatment for autoimmune diseases.
Strategic partnership with a focus on innovative technology.
Full Press Release Details
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over
Frequently Asked Questions
What is the focus of the JNJ and Sail collaboration?
The collaboration focuses on advancing in vivo CAR-T therapies for immune-mediated diseases.
What technology will be expanded in this partnership?
The partnership aims to expand Sail's in vivo CAR-T platform across additional therapeutic targets.
Who is Sail Biomedicines?
Sail Biomedicines is a biotechnology company developing in vivo CAR-T therapies.
What type of diseases does the collaboration target?
The collaboration targets immune-mediated diseases through innovative therapies.